摘要
盐酸埃克替尼(icotini bhydrochloride,克美纳TM,浙江贝达药业有限公司生产,规格:100,125,150,200mg)是一种新型口服表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs),临床用于治疗既往接受过1种或2种化疗的局部晚期或转移的非小细胞肺癌。文中对盐酸埃克替尼在中国的I～IIa期临床试验进行了总结,并对其药理作用、药动学、临床和安全性评价进行了综述。
lcotinib hydrochloride is a novel oral epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI）. It is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer （NSCLC） previously treated with one or two chemotherapy. Several phase Ⅰ and Ⅱa trials in both healthy volunteers and NSCLC patients have been conducted in China recently. In this review we summarized the brief results from these trials, the pharmacology and pharmacokinetics of icotinib hydrochloride.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第18期1691-1694,共4页
Chinese Journal of New Drugs
关键词
盐酸埃克替尼
非小细胞肺癌
表皮生长因子受体酪氨酸激酶抑制剂
药理学
药动学
icotinib hydrochloride
non-small cell tung cancer （NSCLC）
epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI）
pharmacology
pharmacokinetics
